Patients with persistent ALT elevation despite controlled HBV should undergo evaluation for metabolic risk and fatty liver disease.
Researchers studied 61 HIV-infected individuals who switched from efavirenz- to integrase strand transfer inhibitor (INSTI)-based therapies.
Researchers evaluated the results of multiple phase 2 and phase 3 clinical trials and found that drug resistance to darunavir, an HIV protease inhibitor, is rare.
A team of investigators conducted an individual patient data meta-analysis to evaluate how treatment for tuberculosis and antiretroviral therapy affect the risk of mortality in patients with HIV and multidrug-resistant tuberculosis.
In post-hoc analyses, researchers analyzed alcohol use data and whole-blood samples from 359 participants in the New Orleans Alcohol Use in HIV study to explore the association between intestinal leak, dysbiosis, and T cells.
Previously, Dovato was only approved for treatment-naïve adults.
A novel tenofovir urine immunoassay demonstrated predictive utility and may adequately determine PrEP adherence.
A first clinical experience with brodalumab in an HIV-positive patient proves successful and may imply the utility of brodalumab in this patient group.
By providing bundled HIV and HCV testing, substance use disorder treatment programs may create increased awareness of infection status among people with substance abuse disorders.
Despite treatment with antiretroviral therapies, people with HIV may be more likely to experience severe manifestations of COVID-19.
A cross-sectional study was performed to assess whether age, body mass index, and/or components of antiretroviral therapy contributed to persistence of HIV viremia.
A team of investigators conducted a randomized trial comparing test-guided management of tuberculosis with systematic empirical treatment for adults with HIV infection.
A working group comprising members with expertise in virology, molecular epidemiology, public health, bioethics, community engagement, social work, community-based HIV research, and law was assembled to address ethical challenges in US-based HIV phylogenetic research.
A small molecule that disrupts the functions of the HIV capsid protein, GS-6207, demonstrates a reduction in plasma viral load and shows sustained plasma exposure.
Efforts to reduce new HIV infections in children worldwide are faltering.
Fenway Health has created a PrEP Action Kit that provides a roadmap for other health care organizations to implement and/or advance existing PrEP prescription programs.
The FDA has approved Rukobia (fostemsavir; ViiV Healthcare), in combination with other antiretrovirals, for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen due to resistance, intolerance, or safety considerations.
A study evaluated 5 commercially available assays that are approved for HIV seropositivity confirmation and could be readily performed in clinical laboratories.
HIV testing occurs at less than 1 percent of physician office and emergency department visits and at less than 3 percent of community health center (CHC) visits.
HIV-positive patients in the United States face significant challenges associated with poor adherence to antiretroviral therapy (ART) and HIV-1 drug resistance, according to a study published in AIDS and Behavior.